PIDGN: An explainable multimodal deep learning framework for early prediction of Parkinson's disease.

J Neurosci Methods

School of Mathematics and Statistics, Ludong University, Yantai 264025, China. Electronic address:

Published: January 2025

Background: Parkinson's disease (PD), the second most common neurodegenerative disease in the world, is usually not diagnosed until the later stages of the disease, when patients might have already missed the best treatment period. Therefore, more effective prediction methods based on artificial intelligence (AI) are needed to assist physicians in timely diagnosis.

New Methods: An explainable deep learning-based early Parkinson's disease diagnostic model, Parkinson's Integrative Diagnostic Gated Network (PIDGN), was designed by fusing Single Nucleotide Polymorphism (SNP) and brain sMRI data. Firstly, unimodal internal information was extracted using EmsembleTree dimensionality reduction method, Transformer encoder and 3D ResNet. Secondly, gated attention fusion technique was utilized to explore the inter-modal interactions. Finally, the classification results were output through the fully connected layer. SHapley additive interpretation (SHAP) values and Gradient-weighted Class Activation Mapping (GradCAM) techniques were used to help explain the importance of SNPs and brain regions for PD.

Results: The results showed that the PIDGN model achieved the best results with the accuracy of 0.858 and AUROC of 0.897. Top 20 SNPs and the brain regions near the midbrain potentially related to PD were identified using two explainable techniques via SHAP values and GradCAM respectively.

Comparison With Existing Methods And Conclusion: The PIDGN model trained by fusing genetic and imaging data outperforms 13 other commonly used unimodal or bimodal models. Explainable PIDGN model helps deepen understanding of several SNPs and sMRI key factors that may affect PD. This study provides a potentially effective solution for automated early diagnosis of PD using AI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneumeth.2025.110363DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
12
pidgn model
12
shap values
8
snps brain
8
brain regions
8
pidgn
5
disease
5
pidgn explainable
4
explainable multimodal
4
multimodal deep
4

Similar Publications

Parkinson's disease (PD) stands as the sec most prevalent incapacitating neurodegenerative disorder characterized by deterioration of dopamine-producing neurons in the substantia nigra. Coenzyme Q10 (CoQ10) has garnered attention as a potential antioxidant, anti-inflammatory agent and enhancer of mitochondrial complex-I activity. This study aimed to examine and compare the effectiveness of liposomal and non-encapsulated CoQ10 in rotenone induced-PD mouse model over a 21-day treatment duration.

View Article and Find Full Text PDF

Melanoma is the fifth most common skin cancer in the UK, accounting for 4% of all new cancer cases, with a predicted 7% increase in incidence between 2014-35. In parallel, since the initial publication of the Melanoma NICE Guidelines in 2015, there has been a paradigm shift in the management of the disease, with the introduction of effective systemic therapies. These innovations have reshaped the management of melanoma throughout the patient journey, and improved clinical outcomes.

View Article and Find Full Text PDF

Background: Constipation is one of the most common non-motor symptoms in patients with Parkinson's disease (PD), which could manifest during the early stage of the disease. However, the etiology of constipation in PD remains largely unknown. Previous studies supported that gastrointestinal dysfunction may be associated with functional connectivity alterations in paraventricular hypothalamic nucleus (PVN).

View Article and Find Full Text PDF

Cross-titration from risperidone to clozapine utilizing clozapine serum concentrations: A case report.

Pharmacotherapy

January 2025

Department of Pharmacy Practice, School of Pharmacy, Westbrook College of Health Professions, University of New England, Portland, Maine, USA.

Introduction: Clozapine and risperidone are second-generation antipsychotics used in the treatment of schizophrenia. There are no guidelines on cross-titration of antipsychotics and, additionally, there is a paucity of published data to support the potential utility of using serum drug levels to guide dosing in these situations.

Case Report: A 68-year-old female patient with a history of schizophrenia, taking risperidone and fluoxetine, and a recent diagnosis of Parkinson's disease was admitted to the hospital after a fall at home.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!